The clinical pharmacokinetics of escitalopram (Q34610822)

3 August 2017

1 reference

title

The clinical pharmacokinetics of escitalopram (English)

1 reference

3 August 2017

1 reference

1 reference

Niranjan Rao

1

1 reference

3 August 2017

1 January 2007

1 reference

Clinical Pharmacokinetics

3 August 2017

1 reference

3 August 2017

46

1 reference

3 August 2017

4

1 reference

3 August 2017

281-290

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200746040-00002

3 August 2017

0 references

cites work

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

12 December 2020

Drug interactions with newer antidepressants: role of human cytochromes P450

1 reference

12 December 2020

Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans

1 reference

12 December 2020

The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects

1 reference

12 December 2020

Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study

1 reference

12 December 2020

The emerging role of cytochrome P450 3A in psychopharmacology

1 reference

12 December 2020

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

12 December 2020

Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities

1 reference

12 December 2020

Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes

1 reference

12 December 2020

Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study

1 reference

12 December 2020

The kinetics of citalopram: single and multiple dose studies in man

1 reference

12 December 2020

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

1 reference

12 December 2020

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

1 reference

12 December 2020

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation

1 reference

12 December 2020

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

1 reference

12 December 2020

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

12 December 2020

High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients

1 reference

12 December 2020

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.

1 reference

12 December 2020

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

1 reference

12 December 2020

Citalopram: interaction studies with levomepromazine, imipramine, and lithium

1 reference

12 December 2020

Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption

1 reference

12 December 2020

Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.

1 reference

12 December 2020

Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver

1 reference

12 December 2020

Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.

1 reference

12 December 2020

Inhibition of P-glycoprotein by newer antidepressants

1 reference

12 December 2020

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

1 reference

12 December 2020

Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.

1 reference

12 December 2020

Escitalopram versus citalopram: the surprising role of the R-enantiomer

1 reference

12 December 2020

The pharmacokinetics of escitalopram in patients with hepatic impairment

1 reference

12 December 2020

Effect of citalopram on plasma levels of oral theophylline.

1 reference

12 December 2020

Lack of citalopram effect on oral digoxin pharmacokinetics

1 reference

12 December 2020

Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium.

1 reference

12 December 2020

Escitalopram : a review of its use in the management of major depressive and anxiety disorders

1 reference

12 December 2020

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model

1 reference

12 December 2020

Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography

1 reference

12 December 2020

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

1 reference

12 December 2020

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

12 December 2020

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram

1 reference

12 December 2020

Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC

1 reference

12 December 2020

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

1 reference

12 December 2020

Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects

1 reference

12 December 2020

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

1 reference

12 December 2020

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

1 reference

12 December 2020

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

12 December 2020

abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice

1 reference

12 December 2020

In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations

1 reference

12 December 2020

Lack of interaction between citalopram and the CYP3A4 substrate triazolam

1 reference

12 December 2020

Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides

1 reference

12 December 2020

1 reference

12 December 2020

Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences

1 reference

12 December 2020

Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.

1 reference

12 December 2020

10.2165/00003088-200746040-00002

Identifiers

DOI

1 reference

PubMed ID

17375980

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

17375980